8:00 am Coffee & Networking

8:45 am Chair’s Opening Remarks

• Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research

Revolutionizing Solid Tumor Treatments in 2024: Combining Approaches for Effective Targeting and Optimised CAR-T Strategies for Increased Patient Benefits

9:00 am Session Details to Be Confirmed

• Christy Ma Chief Executive Officer, SCG Cell Therapy

9:30 am Harnessing Immune Cell Therapies for Better Clinical Efficacy Against Solid Tumors

• Cecilia Zhang Chief Scientific Officer, Biosyngen

10:00 am Optimizing Clinical Trial Design for Enhanced Efficiency and Patient Outcomes

• Wee Kiat Tan Co-CEO & COO, CytoMed Therapeutics

10:30 am Differentiating National GMP Infrastructure from Industry GMP Setups

• Francesca Lim Chief Medical Officer, Senior Consultant, Deputy Head & Assistant Medical Director, Singapore General Hospital, Singhealth, HSA & ACTRIS

11:00 am Morning Refreshments & Networking

Optimising Robust Manufacturing & CMC Strategies to Fast Track Scaling Up & Scaling Out

12:00 pm Innovative Microfluidic Processing for Autologous Cell Therapy

• Lim An Eng Scientist, Bioprocessing Technology Institute (BTI), A*STAR

12:30 pm Manufacturing Case Study: Preparing from Lab to Trial to Scaling Out

• Lynn Huang Sr. Manager, PharmaEssentia

1:00 pm Commercial Therapy Case Study: Optimising Manufacturing Strategies of CAR-T Cells to Align Capacity to Patient Demand

• Chien-Tsun Kuan President, Chief Executive Officer & Co-Founder, ARCE Therapeutics

1:30 pm Lunch & Networking

Highlighting Key Considerations for Developing Robust Infrastructures for Cell Therapy Commercialisation and Investment

2:30 pm Expanding Horizons: IASO Bio’s Strategic Entry into Southeast Asia

• Alan Fu CFO, Nanjing Iaso Biotherapeutic

3:00 pm Controlling Cost of Goods During Throughout Manufacturing & Scale-Up Operations

• Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research

3:30 pm Afternoon Refreshments & Networking

4:30 pm Gaining Strategic Investments for Cell Therapy Innovations from Venture Lenders & Investors: From Bedside to Bankside, From Wallstreet to Mainstreet

• Yang Liu Vice President & Venture Partner, China Credit Enhancement Corporation

5:00 pm Developing Robust Strategies for Successful Cell Therapy Commercialisation & Market Access

• Rebu Ninan Head of Commercial & Market Access, Cell and Gene Therapies, Immuneel Therapeutics

5:15 pm Close of Summit

5:45 pm Chair’s Closing Remarks

• Joe Yeong Group Leader, A*STAR - Agency for Science Technology and Research